Skip to content

Jonosia asoka 6c in females with abnormal uterine bleeding

Comparative study of phytochemical profiles of jonosia asoka mother tincture produced in-house and in gmp compliant unit, and an open-label clinical trial of jonosia asoka 6C compared to individualized homoeopathy in females of reproductive age with abnormal uterne bleeding. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/101466
Enrollment
44
Registered
2026-01-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified

Interventions

Intervention1: jonosia asoka: 6c potency at the baseline, after 3rd month and 6th month. Control Intervention1: Individualised Homoeopathy: in centesimal potency at baseline, after 3rd month and 6th m

Sponsors

Biswa Ranjan Biswal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Reproductive age group females. Providing written informed consent Reproductive age group females coming under the diagnostic criteria of AUB[(ICD-11-GA2Y)] more than 6 months. Patient who can read or understand English,Hindi,Bengali.

Exclusion criteria

Exclusion criteria: Patient not willing to participate in study. Pregnant, Puerperal women, Lactating mothers. Patients having IUCD in situ. Non-menstrual & non uterine causes for bleeding (Foreign bodies, genital malignancy, abortion, post coital). Severe anaemia(Hb value less than 8gm/dl) History of Bleeding Disorders. Pregnancy related causes,like miscarriage. Patients who are unwilling to give consent or willing to participate in the study. Diagnosed cases of uncontrolled or life threatening illness affecting quality of life or any organ failure. Substance abuse and/or dependence

Design outcomes

Primary

MeasureTime frame
Primary outcome measures are changes in amount of uterine bleeding evaluated by the PBAC. Timepoint: at baseline and after 6 months

Secondary

MeasureTime frame
Change in quality of life assessed through EQ-5D-5L questionnaire. Safety and adverse events. Timepoint: at baseline and after 6 months

Countries

India

Contacts

Public ContactKaushik Deb Das

the calcutta homoepathic medical college and hospital

drkaushikddas25@gmail.com9932298682

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026